Lisa Blixt

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman, Ola Blennow, Lotta Hansson et al. · EBioMedicine · 2021 · 219 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

Lisa Blixt, Gordana Bogdanović, Marcus Buggert et al. · Leukemia · 2021 · 43 citations · Full text

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman, Ola Blennow, Lotta Hansson et al. · 2021 · 24 citations · Full text

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

Lisa Blixt, David Wullimann, Soo Aleman et al. · Haematologica · 2022 · 17 citations · Full text

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Lisa Blixt, Yu Gao, David Wullimann et al. · Blood · 2022 · 12 citations · Full text